Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29, 2025, before market open. This highly anticipated announcement is expected to inject significant volatility into the stock, with analysts
The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
